Drug intelligence / Profile preview

ketorolac + propofol

Development stage
Phase 4
Lead developer
Roche
Modality
Small Molecules
Administration
Intravenous
01

Overview

Ketorolac + propofol is a combination of two pharmaceutical agents used together, typically in perioperative or procedural settings. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties. It acts primarily by inhibiting prostaglandin synthesis through reversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), leading to reduced pain and inflammation[5][8]. Propofol is a sedative-hypnotic agent used for induction and maintenance of anesthesia or sedation. Its primary mechanism involves positive allosteric modulation of the gamma-aminobutyric acid type A (GABA-A) receptor, enhancing inhibitory neurotransmission in the central nervous system[2]. The combination is not available as a fixed-dose commercial product but may be administered together intravenously during procedures to provide both sedation (from propofol) and analgesia (from ketorolac). Clinical studies have shown that this combination can reduce emergence agitation after anesthesia in children[1] and improve recovery profiles during monitored anesthesia care compared to opioid combinations[6].

02

Targets

GABRB2 (GABA-A receptor subunit beta-2)GABRB3 (GABA-A receptor subunit beta-3)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on ketorolac + propofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketorolac + propofol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call